A published report in Surgical Technology International cites the benefits of using autologous [the patient’s own] mesenchymal stem cells [MSCs] to effectively treat degenerative disc disease (DDD). The study also found that the use of stem cells to augment spinal fusion surgery demonstrated an efficacy that met the gold standard for iliac crest bone graft in posterolateral fusion models.
In a review of the published report, Dr. Kenneth K. Hansraj, Chief of Spine Surgery at New York Spine Surgery & Rehabilitation Medicine, stated that “With back problems being a leading culprit of pain both nationally and internationally, the findings of MSC’s to support degenerative disc disease and degenerative spinal conditions can positively impact the lives of countless people across the globe,” said Dr. Hansraj.
As regenerative engineering progresses, the study demonstrates that the best stem cells to use in emerging treatments will be the patient’s own [autologous stem cells] as this negates the need to find a suitable donor and eliminates the chances of rejection of the transplanted tissue. To learn more about banking your own valuable stem cells to insure your family’s future health, visit StemSave or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.